Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Crizotinib master protocol continuation study for ongoing Pfizer trial participants
CTR20222880Phase 4Active
- Sponsor
- Pfizer
- Start
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of crizotinib in non-small cell lung cancer (NSCLC), sponsored by Pfizer. Started Mar 2023; status: active.
02
Drugs
crizotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20222880.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20222880.